Vivesto AB (VIVE.ST)
SEK 0.27
(-1.45%)
SEK 0.27
(-1.45%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2022 | 355.87 Million SEK | -40.12% |
| 2021 | 594.3 Million SEK | -31.18% |
| 2020 | 863.54 Million SEK | -14.11% |
| 2019 | 1 Billion SEK | 55.54% |
| 2018 | 646.37 Million SEK | 13.78% |
| 2017 | 568.07 Million SEK | 8.91% |
| 2016 | 521.58 Million SEK | 1.16% |
| 2015 | 515.57 Million SEK | 0.2% |
| 2014 | 514.56 Million SEK | 9.86% |
| 2013 | 468.38 Million SEK | 5.21% |
| 2012 | 445.17 Million SEK | 27.26% |
| 2011 | 349.8 Million SEK | 9.21% |
| 2010 | 320.31 Million SEK | 78.3% |
| 2009 | 179.65 Million SEK | 85.02% |
| 2008 | 97.09 Million SEK | 10.75% |
| 2007 | 87.67 Million SEK | -27.42% |
| 2006 | 120.79 Million SEK | 89.64% |
| 2005 | 63.69 Million SEK | 76.63% |
| 2004 | 36.06 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q2 | 306.93 Million SEK | -7.08% |
| 2023 Q1 | 330.32 Million SEK | -7.18% |
| 2022 Q2 | 651.49 Million SEK | -7.16% |
| 2022 Q4 | 355.87 Million SEK | -37.92% |
| 2022 FY | 355.87 Million SEK | -40.12% |
| 2022 Q3 | 573.23 Million SEK | -12.01% |
| 2022 Q1 | 701.76 Million SEK | 18.08% |
| 2021 Q3 | 693.3 Million SEK | -8.93% |
| 2021 Q2 | 761.28 Million SEK | -7.58% |
| 2021 FY | 594.3 Million SEK | -31.18% |
| 2021 Q1 | 823.76 Million SEK | -4.61% |
| 2021 Q4 | 594.3 Million SEK | -14.28% |
| 2020 Q2 | 942.78 Million SEK | -6.22% |
| 2020 Q4 | 863.54 Million SEK | -5.65% |
| 2020 FY | 863.54 Million SEK | -14.11% |
| 2020 Q3 | 915.23 Million SEK | -2.92% |
| 2020 Q1 | 1 Billion SEK | 14.7% |
| 2019 Q4 | 876.47 Million SEK | 46.06% |
| 2019 Q1 | 646.37 Million SEK | 14.84% |
| 2019 FY | 1 Billion SEK | 55.54% |
| 2019 Q2 | 669.3 Million SEK | 3.55% |
| 2019 Q3 | 600.08 Million SEK | -10.34% |
| 2018 Q3 | 598.9 Million SEK | 11.16% |
| 2018 Q4 | 562.82 Million SEK | -6.02% |
| 2018 Q2 | 538.76 Million SEK | -5.16% |
| 2018 FY | 646.37 Million SEK | 13.78% |
| 2018 Q1 | 568.07 Million SEK | 0.92% |
| 2017 FY | 568.07 Million SEK | 8.91% |
| 2017 Q4 | 562.88 Million SEK | -0.95% |
| 2017 Q3 | 568.27 Million SEK | -8.77% |
| 2017 Q2 | 622.92 Million SEK | 19.43% |
| 2017 Q1 | 521.58 Million SEK | -0.06% |
| 2016 Q1 | 515.57 Million SEK | 0.23% |
| 2016 FY | 521.58 Million SEK | 1.16% |
| 2016 Q4 | 521.88 Million SEK | -1.15% |
| 2016 Q3 | 527.94 Million SEK | 2.14% |
| 2016 Q2 | 516.87 Million SEK | 0.25% |
| 2015 Q2 | 490.11 Million SEK | -4.75% |
| 2015 Q4 | 514.39 Million SEK | -5.06% |
| 2015 Q1 | 514.56 Million SEK | -4.67% |
| 2015 FY | 515.57 Million SEK | 0.2% |
| 2015 Q3 | 541.82 Million SEK | 10.55% |
| 2014 Q1 | 468.38 Million SEK | 880.02% |
| 2014 Q4 | 539.77 Million SEK | 17.75% |
| 2014 Q3 | 458.42 Million SEK | -5.48% |
| 2014 Q2 | 485.01 Million SEK | 3.55% |
| 2014 FY | 514.56 Million SEK | 9.86% |
| 2013 Q1 | 445.17 Million SEK | 728.32% |
| 2013 FY | 468.38 Million SEK | 5.21% |
| 2013 Q3 | 407.52 Million SEK | -4.35% |
| 2013 Q4 | 47.79 Million SEK | -88.27% |
| 2013 Q2 | 426.05 Million SEK | -4.3% |
| 2012 Q1 | 349.8 Million SEK | 8.72% |
| 2012 Q4 | 53.74 Million SEK | -85.9% |
| 2012 FY | 445.17 Million SEK | 27.26% |
| 2012 Q2 | 372.76 Million SEK | 6.56% |
| 2012 Q3 | 381.26 Million SEK | 2.28% |
| 2011 Q3 | 38 Million SEK | -87.65% |
| 2011 Q2 | 307.75 Million SEK | -3.92% |
| 2011 Q4 | 321.74 Million SEK | 746.64% |
| 2011 FY | 349.8 Million SEK | 9.21% |
| 2011 Q1 | 320.31 Million SEK | -6.07% |
| 2010 Q4 | 341 Million SEK | 56.29% |
| 2010 FY | 320.31 Million SEK | 78.3% |
| 2010 Q3 | 218.18 Million SEK | 12.39% |
| 2010 Q2 | 194.13 Million SEK | 8.06% |
| 2010 Q1 | 179.65 Million SEK | 0.0% |
| 2009 FY | 179.65 Million SEK | 85.02% |
| 2008 FY | 97.09 Million SEK | 10.75% |
| 2007 FY | 87.67 Million SEK | -27.42% |
| 2006 FY | 120.79 Million SEK | 89.64% |
| 2005 FY | 63.69 Million SEK | 76.63% |
| 2004 FY | 36.06 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AcuCort AB | 58.5 Million SEK | -508.262% |
| AlzeCure Pharma AB (publ) | 32 Million SEK | -1012.078% |
| BioGaia AB (publ) | 2.33 Billion SEK | 84.747% |
| Enzymatica AB (publ) | 125.91 Million SEK | -182.641% |
| Enorama Pharma AB (publ) | 34.38 Million SEK | -934.975% |
| Gabather AB (publ) | 2.93 Million SEK | -12016.99% |
| Klaria Pharma Holding AB (publ.) | 73.12 Million SEK | -386.701% |
| Moberg Pharma AB (publ) | 634.73 Million SEK | 43.933% |
| Nanexa AB (publ) | 132.25 Million SEK | -169.079% |
| Newbury Pharmaceuticals AB (publ) | 90.87 Million SEK | -291.628% |
| ODI Pharma AB | 12.27 Million SEK | -2799.195% |
| Orexo AB (publ) | 786.6 Million SEK | 54.758% |
| Probi AB (publ) | 1.55 Billion SEK | 77.046% |
| Swedencare AB (publ) | 9.52 Billion SEK | 96.263% |
| Swedish Orphan Biovitrum AB (publ) | 74.02 Billion SEK | 99.519% |
| Toleranzia AB | 160.42 Million SEK | -121.83% |